[1]
O. Y. . Mishchenko, V. Y. . Adonkina, and I. I. Greshko, “The substantiation of the cost optimization for ER(+) HER2(−) breast cancer hormone therapy based on the results of the cost minimization pharmacoeconomic analysis”, Soc. pharm. health care, vol. 11, no. 1, pp. 72–79, May 2025.